CAR-T Therapy: Approach to Bridging
Panelists explain how CAR-T cell therapy works and describe the treatment process, discussing whether CAR -T is considered a complex procedure at their institution or if the logistics have been streamlined into clinical workflows, and they also detail their institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion, including whether patients are managed in-house or sent back to community centers.
EP: 1.Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma
EP: 2.Patient Selection and Referral Eligibility for CAR-T Therapy
EP: 3.Understanding the CAR-T Treatment Process
EP: 4.CAR-T Therapy: Approach to Bridging
EP: 5.Care Coordination and Transition Strategies for CAR-T Therapy
EP: 6.CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
EP: 7.Key Takeaways in CAR-T Therapy for Multiple Myeloma
Video content above is prompted by the following:
- Could you explain how CAR-T cell therapy works and describe the treatment process?
- Do you consider CAR-T therapy a complex process at your institution, or have you been able to streamline the logistics and integration into clinical workflows?
- Can you explain your institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion?
- Do you send patients back to community centers or is does it the treatment happen done in-house?
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
